News

Pfizer to buy Biohaven Pharmaceutical in $11.6 billion deal

In this article

PFE

BHVN

Biohaven Pharmaceutical CEO Vlad Coric
Source: CNBC

Pfizer said on Tuesday it will buy migraine drug maker Biohaven Pharmaceutical Holding for about $11.6 billion in cash.

Pfizer will acquire all the outstanding shares of Biohaven not already owned by Pfizer for $148.50 per share in cash, a 78.6% premium to Biohaven’s last closing price.

Biohaven shareholders, including Pfizer, will also get 0.5 of a share of a new publicly traded company that will retain Biohaven’s non-migraine treatments that are in development stage.

In November, Pfizer acquired overseas marketing rights to two migraine drugs from Biohaven for up to $1.24 billion, with Pfizer taking a 2.6% equity stake in the smaller company.

This story is developing. Please check back for updates.

What's your reaction?

Excited
0
Happy
0
In Love
0
Not Sure
0
Silly
0

You may also like

Leave a reply

Your email address will not be published. Required fields are marked *

More in:News